share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/30 16:28

Moomoo AI 已提取核心訊息

Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 30, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. Following this transaction, Gibson's direct holdings in the company increased to a total of 762,656 shares. The transaction is currently reported as in progress.
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 30, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. Following this transaction, Gibson's direct holdings in the company increased to a total of 762,656 shares. The transaction is currently reported as in progress.
Recursion Pharmaceuticals的首席執行官Christopher Gibson已參與公司股票購買交易。2024年8月30日,Gibson以每股2.48美元的價格購買了Recursion Pharmaceuticals的5000股A類普通股。在此交易之後,Gibson直接持有公司的股份數增至762,656股。該交易目前被報告爲進行中。
Recursion Pharmaceuticals的首席執行官Christopher Gibson已參與公司股票購買交易。2024年8月30日,Gibson以每股2.48美元的價格購買了Recursion Pharmaceuticals的5000股A類普通股。在此交易之後,Gibson直接持有公司的股份數增至762,656股。該交易目前被報告爲進行中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息